Wanbangde Pharmaceutical Holding Group (002082.SZ): Obtained drug registration certificate for sildenafil oral suspension

Wanbangde Pharmaceutical Holding Group (002082.SZ) announced that its wholly-owned subsidiary Wanbangde Pharmaceutical Holding Group Pharmaceutical Group Zhejiang Medicine Sales Co., Ltd. (referred to as "Wanbangde Pharmaceutical Holding Group Sales Company") has obtained the exclusive import and sales rights for Farmalider, S.A.'s oral suspension of citrate sildenafil (referred to as "sildenafil oral suspension") in the mainland China market for a period of 10 years. Recently, they received notification from Farmalider's authorized party NULIFE GROUPE LIMITED, that the sildenafil oral suspension has obtained the "Drug Registration Certificate" issued by the National Medical Products Administration. The sildenafil oral suspension is a selective inhibitor of type 5 phosphodiesterase (PDE5) specific for cyclic guanosine monophosphate (cGMP), clinically used for the treatment of male erectile dysfunction (ED). The issuance of the "Drug Registration Certificate" for the sildenafil oral suspension signifies that the company will have exclusive rights for importing and selling the product in the mainland China market for the next 10 years. By introducing innovative formulations into the field of ED, the company can better meet the medication needs of different groups.